MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy

The MIB‐1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB‐1 labeling index at the time of diag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Yamamoto, Eri, Tomita, Naoto, Sakata, Seiji, Tsuyama, Naoko, Takeuchi, Kengo, Nakajima, Yuki, Miyashita, Kazuho, Tachibana, Takayoshi, Takasaki, Hirotaka, Tanaka, Masatsugu, Hashimoto, Chizuko, Koharazawa, Hideyuki, Fujimaki, Katsumichi, Taguchi, Jun, Harano, Hiroshi, Motomura, Shigeki, Ishigatsubo, Yoshiaki
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2013
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653523/
https://ncbi.nlm.nih.gov/pubmed/24112697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12288
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky